Invention Grant
- Patent Title: Soluble CD80 as a therapeutic to reverse immune suppression in cancer patients
-
Application No.: US15492535Application Date: 2017-04-20
-
Publication No.: US10377810B2Publication Date: 2019-08-13
- Inventor: Suzanne Ostrand-Rosenberg
- Applicant: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
- Applicant Address: US MD Baltimore
- Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
- Current Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
- Current Assignee Address: US MD Baltimore
- Agency: Olive Law Group, PLLC
- Agent Tristan A. Fuierer; Marianne Fuierer
- Main IPC: C07K14/00
- IPC: C07K14/00 ; C07K14/705 ; A61K39/395 ; A61K31/7088 ; C07K16/00 ; C07K16/28
Abstract:
The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.
Public/Granted literature
- US20170226181A1 SOLUBLE CD80 AS A THERAPEUTIC TO REVERSE IMMUNE SUPPRESSION IN CANCER PATIENTS Public/Granted day:2017-08-10
Information query
